Allied Biotech Corporation Sustainability Profile
Allied Biotech Corporation, a leading name in the biotechnology sector, is headquartered in Taiwan (TW) and operates extensively across Asia, Europe, and North America. Founded in 1995, the company has established itself as a pioneer in the development of innovative biopharmaceuticals and advanced drug delivery systems. Specialising in the production of high-quality excipients and active pharmaceutical ingredients (APIs), Allied Biotech is renowned for its commitment to quality and regulatory compliance. Their unique offerings, including proprietary formulations and customised solutions, cater to a diverse range of therapeutic areas. With a strong market position, Allied Biotech has achieved significant milestones, including numerous partnerships with global pharmaceutical companies. Their dedication to research and development continues to drive advancements in the industry, solidifying their reputation as a trusted partner in biopharmaceutical innovation.
DitchCarbon Score
How does Allied Biotech Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Allied Biotech Corporation's score of 20 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Allied Biotech Corporation's reported carbon emissions
In 2023, Allied Biotech Corporation reported total carbon emissions of approximately 5,519,770 kg CO2e. This figure represents a slight decrease from 2022, when emissions were about 5,718,830 kg CO2e. The company has set ambitious reduction targets, aiming for a 10% decrease in total carbon emissions across both Scope 1 and Scope 2 by the end of 2023, starting from 2021 levels. Allied Biotech's emissions data does not currently specify Scope 3 emissions, and there is no disclosed data on upstream or downstream emissions categories. The company has not cascaded emissions data from any parent organisation, indicating that its reported figures are independently sourced. The reduction initiatives reflect a commitment to sustainability and climate responsibility, aligning with industry standards for carbon management. The company’s emissions intensity is reported at about 0.00008 metric tons CO2e per NT$ million in revenue, showcasing its efforts to integrate environmental considerations into its operational framework.
How Carbon Intensive is Allied Biotech Corporation's Industry?
How Carbon Intensive is Allied Biotech Corporation's Location?
Allied Biotech Corporation's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Allied Biotech Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
